Vaginal Dryness & GSM Treatment Guide

Most of my patients are surprised to learn that vaginal dryness is not just a minor inconvenience — it is a chronic, progressive condition with a formal medical name and multiple FDA-approved treatments. The medical community now calls it genitourinary syndrome of menopause (GSM), a term introduced to replace the older phrase "vulvovaginal atrophy" and to better capture the full scope of what low estrogen does to the vagina, vulva, and urinary tract together.^[1]

What I see most often in my practice is patients who have been quietly tolerating symptoms for years — painful intercourse, dryness, burning, recurrent urinary tract infections — because they assumed it was just part of getting older, or because they were nervous about hormone therapy. The treatment conversation is more straightforward than most patients expect, and the options are better than they were even a decade ago.

This guide covers what GSM actually is, why it happens, what the evidence supports for treatment, and how telehealth fits into the picture. I've written it to reflect the 2020 NAMS GSM Position Statement and current ACOG guidance — the same sources that inform clinical practice today.

What Is Genitourinary Syndrome of Menopause?

The term GSM was formally introduced in 2014 by a joint working group from the North American Menopause Society (NAMS) and the International Society for the Study of Women's Sexual Health. The name change was deliberate — "vulvovaginal atrophy" described only part of the picture, and it carried a stigma that discouraged women from discussing their symptoms with clinicians.

GSM describes the collection of changes that happen to the vagina, vulva, labia, clitoris, urethra, and bladder when estrogen levels fall. Estrogen is not just a reproductive hormone — it is responsible for maintaining the thickness, elasticity, lubrication, and acid pH of vaginal tissue. When estrogen drops, the vaginal lining thins, the pH rises, lubrication decreases, and the tissue becomes more fragile and prone to irritation.

The 2020 NAMS Position Statement found that GSM affects approximately 27% to 84% of postmenopausal women.^[1] That wide range reflects how differently women experience and report symptoms. In one study of more than 900 women undergoing routine examinations, GSM was identified in 84% of women six years after menopause — most of whom had not volunteered their symptoms spontaneously. The reluctance to raise these concerns is one of the central reasons GSM remains undertreated.

How GSM Differs from Hot Flashes

Hot flashes and night sweats — the vasomotor symptoms of menopause — typically improve on their own within a few years. GSM does the opposite. Without treatment, the structural and tissue changes in the vagina and urinary tract tend to get worse over time, not better. This is why early treatment has real value: it is far easier to maintain healthy tissue than to restore significantly atrophied tissue.

Symptoms of GSM

Symptoms span two overlapping categories: vaginal and urinary.

• Vaginal symptoms: dryness, burning, irritation, itching, reduced lubrication, painful intercourse (dyspareunia), light bleeding after sex, and vaginal discharge
• Urinary symptoms: urgency, frequency, burning with urination (dysuria), recurrent urinary tract infections, and stress urinary incontinence

Not every woman experiences all of these. Some patients present primarily with sexual symptoms; others come in mainly because of recurrent UTIs. Recognizing both symptom clusters as part of the same underlying process matters for treatment — because treating the root cause (low estrogen) often addresses both at once.

Causes Beyond Menopause

Menopause is the most common cause of GSM, but estrogen deficiency is not limited to menopause. Several other situations produce the same hormonal environment and the same symptoms.

Breastfeeding

Lactation suppresses estrogen through elevated prolactin levels, creating a temporary hypoestrogenic state that closely resembles menopause. Breastfeeding women frequently report vaginal dryness and painful intercourse that resolves once they stop nursing and estrogen levels recover. This is entirely normal, and it's worth flagging for postpartum patients who may otherwise worry there is something wrong.

Medications

Antihistamines (diphenhydramine, loratadine, cetirizine) have drying effects on mucous membranes throughout the body — this includes the vagina. Women who take antihistamines regularly for allergies often notice increased dryness. Certain antidepressants — particularly SSRIs and SNRIs — can reduce vaginal lubrication through their effects on serotonin signaling and blood flow. Aromatase inhibitors, used in breast cancer treatment, deliberately suppress estrogen production and commonly cause severe GSM symptoms.

Sjögren's Syndrome

Sjögren's is an autoimmune condition that targets moisture-producing glands. Women with Sjögren's syndrome report vaginal dryness 2–3 times more often than comparably aged women without the disease.^[5] The mechanism is different from estrogen deficiency — it involves lymphocytic infiltration and vascular dysfunction in vaginal tissue — which means estrogen therapy alone may not fully resolve symptoms in this population. Vaginal moisturizers and lubricants remain important treatment components.

Cancer Treatment

Chemotherapy can cause ovarian failure and abrupt menopause in premenopausal women. Pelvic radiation damages vaginal tissue directly. Both scenarios produce GSM symptoms that can be severe and permanent. Managing vaginal health proactively during and after cancer treatment is an important but often neglected part of survivorship care.

Non-Hormonal Options: Moisturizers and Lubricants

For mild to moderate symptoms, and as a foundation of treatment regardless of what else you add, non-hormonal vaginal products are the starting point. There's a meaningful distinction between moisturizers and lubricants that most patients don't know — and getting it right makes a difference.

Vaginal Moisturizers

Vaginal moisturizers work like a facial moisturizer: they are used regularly (typically every 2–3 days) to maintain tissue hydration over time. They do not replace estrogen or reverse the structural changes of GSM, but they can significantly reduce dryness, burning, and irritation. Products with hyaluronic acid have shown promise in clinical studies — hyaluronic acid is a naturally occurring molecule in connective tissue that retains water and has been used topically for tissue repair.^[1] Brand options include Replens (polycarbophil-based), and several newer hyaluronic acid formulations.

Consistency matters. A vaginal moisturizer used twice a week provides cumulative benefit; using it only on the days symptoms are noticeable produces much less improvement. What I tell my patients is to treat it like a skincare routine — it works best when it becomes a habit.

Lubricants for Sexual Activity

Lubricants are used during sexual activity to reduce friction in the moment. They do not provide the sustained tissue hydration that a moisturizer offers, but they are essential for comfort during intercourse. Three types are available, each with distinct properties:

Osmolality deserves more attention than it typically gets. Osmolality measures the concentration of dissolved particles in a solution. The vagina has a natural osmolality of around 300 mOsm/kg. When a lubricant has very high osmolality — some popular brands exceed 3,000 mOsm/kg — the vaginal cells push water out of themselves trying to equalize, which dries tissue rather than lubricating it and increases the risk of irritation and infection. The WHO recommends lubricant osmolality below 380 mOsm/kg for vaginal use.^[6] If a product does not list osmolality, assume it is high — brands with low osmolality tend to advertise it prominently.

Low-Dose Vaginal Estrogen: What You Need to Know

Low-dose vaginal estrogen is the most effective treatment for GSM and the one I turn to most often for patients with moderate to severe symptoms. The 2020 NAMS Position Statement describes it as safe, effective, and well-tolerated — and the evidence behind that statement is substantial.^[1]

The word "estrogen" in the name understandably gives some patients pause. The critical point to understand is that low-dose vaginal estrogen works locally. It is not the same as systemic hormone therapy. The doses are small, the delivery is local, and the amount that reaches the bloodstream is minimal — typically keeping blood estrogen levels within the normal postmenopausal range. This distinction changes the risk profile significantly.

Available Formulations

Do You Need Progesterone With Vaginal Estrogen?

No. Women using only low-dose vaginal estrogen do not need to add a progestogen for uterine protection. This is because systemic absorption is minimal — not enough estrogen reaches the endometrium (uterine lining) to stimulate abnormal growth. This holds for tablets, the ring, and low-dose cream. Higher-dose vaginal estrogen cream preparations can produce more absorption and warrant individual assessment.

How Long Until It Works?

Meaningful improvement typically begins within 4–6 weeks. Full benefit — restored tissue thickness, improved lubrication, reduced urinary symptoms — generally takes 12 weeks of consistent use. The tissue repair is gradual because the vaginal lining rebuilds itself over multiple cell turnover cycles. Stopping treatment returns symptoms over time, so ongoing maintenance use is typically recommended.

Vaginal Estrogen and Breast Cancer Survivors

This is the conversation I have most carefully in my practice. Women who have had breast cancer experience GSM at high rates — often because chemotherapy, radiation, or endocrine therapies suppress estrogen — and yet they are frequently told they cannot use estrogen of any kind. The actual clinical picture is more specific than that.

ACOG's 2021 Clinical Consensus states that available evidence suggests low-dose vaginal estrogen is safe for individuals with a history of hormone receptor–positive breast cancer who are at low risk for recurrence and who do not respond to non-hormonal treatments.^[2] A large population study found comparable breast cancer recurrence rates between women who used vaginal estrogen and those who did not — with no significant difference in all-cause mortality at five years, and actually a reduced all-cause mortality risk at ten years in the vaginal estrogen group.^[3]

The more complicated group is women on aromatase inhibitors (AIs) — medications like anastrozole, letrozole, and exemestane that are prescribed after hormone receptor–positive breast cancer. AIs work by suppressing the conversion of androgens to estrogen throughout the body. Some data suggest that concurrent vaginal estrogen use may partially counteract AIs, and one large cohort study observed a higher recurrence rate in women prescribed both. Other studies have not confirmed this finding. The evidence is genuinely conflicting, and this is an area that requires an individual conversation with the patient's oncologist.^[3]

Ospemifene (Osphena): The Oral Option

Ospemifene (brand name Osphena) is an oral selective estrogen receptor modulator (SERM) approved by the FDA for moderate to severe vaginal dryness and painful intercourse due to menopause. It is taken as a once-daily 60 mg tablet with food.

SERMs work by binding to estrogen receptors and acting differently depending on the tissue. Ospemifene acts like an estrogen agonist on vaginal tissue — improving tissue thickness, lubrication, and the vaginal pH — while behaving as a neutral or antagonist agent in breast tissue. Clinical trials demonstrated significant improvement in dyspareunia and vaginal dryness compared to placebo, and clinical studies have not shown increased breast cancer incidence or recurrence.^[7]

Ospemifene is a good fit for women who:

• Prefer an oral medication over vaginal application
• Have difficulty with vaginal insertion due to severe atrophy or other conditions
• Want an estrogen-free option with systemic reach

It is not appropriate for women with a history of venous thromboembolism (blood clots), active cardiovascular disease, estrogen-dependent cancers, or those taking certain medications. Like all SERMs, it requires a thorough medication and history review before prescribing. Because ospemifene acts systemically, it does carry a label warning about potential endometrial effects — women with an intact uterus who take ospemifene long-term may need periodic monitoring.

Prasterone / DHEA Vaginal Insert (Intrarosa)

Prasterone (brand name Intrarosa) is a vaginal insert containing dehydroepiandrosterone (DHEA), a naturally occurring hormone that the body converts locally into both estrogen and testosterone within vaginal tissue. The FDA approved it in 2016 for the treatment of moderate to severe dyspareunia due to menopause.

The key feature of prasterone is its mechanism: it delivers hormone precursors directly to vaginal tissue, where they are converted to active hormones locally. Serum levels of estrogen and testosterone remain within the normal postmenopausal range — the hormonal activity stays where it is needed.^[8] This is a different approach from vaginal estrogen (which delivers estrogen directly) or ospemifene (which works systemically).

Clinical trials showed significant improvement in vaginal dryness, painful intercourse, and vaginal tissue appearance compared to placebo. The insert is used once daily at bedtime. Because prasterone does not raise systemic estrogen levels in a clinically meaningful way, it has been studied in breast cancer survivors — including those on aromatase inhibitors — with no signal of increased cancer risk in available data, though long-term safety data remain limited.

Vaginal Laser Therapy: What the Evidence Shows

Energy-based devices — fractional CO₂ laser and radiofrequency treatments — have been marketed for vaginal rejuvenation and GSM under various brand names. You may have seen these advertised at medical spas or gynecology offices. The evidence behind them does not support their routine use.

Some newer small studies suggest that laser therapy may improve certain GSM symptoms, and clinical trials are ongoing. But meaningful long-term safety and efficacy data are not yet available. The current position of most major professional societies — including NAMS — is that vaginal laser therapy should not be offered as a standard treatment outside of clinical trials until better evidence exists. Most insurance plans do not cover these procedures, and out-of-pocket costs can be substantial.

If you are being offered vaginal laser therapy for GSM, ask specifically what evidence the provider is citing and whether FDA-approved alternatives have been tried first. That is a reasonable thing to ask.

Impact on Sexual Function and Urinary Health

GSM affects more than physical tissue — it affects relationships, self-image, and quality of life in ways that patients often carry quietly. In survey data cited by the 2020 NAMS Position Statement, GSM-related symptoms detracted from enjoyment of sex in 59% of affected women, interfered with relationships in 47%, negatively affected sleep in 29%, and adversely affected general enjoyment of life in 27%.^[1]

Painful intercourse — dyspareunia — deserves direct clinical attention. It is not a normal consequence of aging that women should accept. When intercourse is painful, many women avoid sexual activity altogether, which leads to further vaginal disuse, worsening atrophy, and relationship strain. Regular sexual activity (including solo activity) with adequate lubrication actually helps maintain vaginal tissue by stimulating circulation and maintaining elasticity. This is not folklore — it is supported by the physiology.

Urinary Symptoms

The urethra and bladder trigone (the base of the bladder) are estrogen-sensitive tissues. When estrogen levels fall, these tissues thin and become less resilient, contributing to urgency, frequency, burning with urination, and increased susceptibility to urinary tract infections. Vaginal estrogen therapy has been shown to reduce recurrent UTI rates by 50–70% in postmenopausal women — one of the strongest reasons to treat GSM even when urinary symptoms rather than vaginal symptoms are the primary complaint.^[1]

Stress urinary incontinence (leaking with coughing, sneezing, or exercise) also has a hormonal component. While pelvic floor physical therapy is the first-line intervention, vaginal estrogen can support tissue health in a way that enhances the benefit of pelvic floor exercises.

Telehealth for GSM: What Can Be Managed Remotely

Low-dose vaginal estrogen, ospemifene, and prasterone are all prescribable through a telehealth visit. The clinical evaluation required is a thorough history — symptom assessment, medical history review, current medications, and assessment for contraindications such as unexplained vaginal bleeding, history of blood clots, or relevant cancer history.

Telehealth is a good fit for GSM prescribing for several practical reasons. Many patients are reluctant to raise these symptoms in a busy office visit — the privacy and directness of a video consultation often makes it easier to have the conversation in full. The physical exam, while useful for documenting objective findings, does not change the treatment decision for most straightforward GSM presentations. For patients with prior gynecologic history or unusual findings, in-person evaluation remains important.

If you have undiagnosed vaginal bleeding, a history of estrogen-dependent cancer, or active blood clots, an in-person evaluation with a specialist should come first. Telehealth works well for the many patients who have a clear symptom history, no major contraindications, and are ready to start treatment.

Choosing the Right Treatment: A Clinical Framework

No single treatment is right for every patient. The right starting point depends on symptom severity, personal preference, medical history, and whether estrogen-containing products are appropriate. Here is how I approach the decision:

Frequently Asked Questions